心臓発作(Heart Attack):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Heart Attack - Pipeline Review, H1 2015
◆商品コード:GMDHC6306IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年2月18日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における心臓発作(Heart Attack)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・心臓発作(Heart Attack)の概要
・心臓発作(Heart Attack)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・心臓発作(Heart Attack)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・心臓発作(Heart Attack)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・心臓発作(Heart Attack)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Heart Attack – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Heart Attack – Pipeline Review, H1 2015’, provides an overview of the Heart Attack’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Heart Attack, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Heart Attack and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Heart Attack
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Heart Attack and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Heart Attack products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Heart Attack pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Heart Attack
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Heart Attack pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heart Attack Overview 6
Therapeutics Development 7
Pipeline Products for Heart Attack – Overview 7
Pipeline Products for Heart Attack – Comparative Analysis 8
Heart Attack – Therapeutics under Development by Companies 9
Heart Attack – Therapeutics under Investigation by Universities/Institutes 10
Heart Attack – Pipeline Products Glance 11
Early Stage Products 11
Heart Attack – Products under Development by Companies 12
Heart Attack – Products under Investigation by Universities/Institutes 13
Heart Attack – Companies Involved in Therapeutics Development 14
APT Therapeutics, Inc. 14
Lacer, S.A. 15
Lanthio Pharma B.V. 16
Heart Attack – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
AB-002 – Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
APT-102 – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LA-8045 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LWnt-3a – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Lysimab – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NVX-308 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule for Reperfusion Injury and Heart Attack – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit PDE5 for Cardiovascular Disease – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Heart Attack – Recent Pipeline Updates 36
Heart Attack – Dormant Projects 37
Heart Attack – Product Development Milestones 38
Featured News & Press Releases 38
Oct 02, 2014: APT Therapeutics’ Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

[List of Tables]
Number of Products under Development for Heart Attack, H1 2015 7
Number of Products under Development for Heart Attack - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Heart Attack - Pipeline by APT Therapeutics, Inc., H1 2015 14
Heart Attack - Pipeline by Lacer, S.A., H1 2015 15
Heart Attack - Pipeline by Lanthio Pharma B.V., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Heart Attack Therapeutics - Recent Pipeline Updates, H1 2015 36
Heart Attack - Dormant Projects, H1 2015 37

[List of Figures]
Number of Products under Development for Heart Attack, H1 2015 7
Number of Products under Development for Heart Attack - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Molecule Types, H1 2015 23
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

【掲載企業】

APT Therapeutics, Inc.
Lacer, S.A.
Lanthio Pharma B.V.

★調査レポート[心臓発作(Heart Attack):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6306IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[心臓発作(Heart Attack):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆